Can-Fite BioPharma (CANF) Stock Soars 65% Following Positive Pancreatic Cancer Trial Results

Key Highlights

• Shares of Can-Fite BioPharma (CANF) climbed as high as 65% on Wednesday following the release of Phase 2a clinical data for Namodenoson in patients with advanced pancreatic cancer.
• The trial successfully achieved its primary safety objective among 20 enrolled patients who had failed previous standard treatment options.
• Among third-line therapy patients, median overall survival surpassed five months, with 37.5% of participants surviving beyond seven months.
• A notable second-line patient remained alive over 18 months following Namodenoson initiation — representing the trial’s longest-surviving participant.
• The company intends to move forward with a Phase 2b trial evaluating Namodenoson combined with chemotherapy.

Shares of Can-Fite BioPharma (CANF) experienced a dramatic rally of up to 65% during Wednesday’s trading session after the biotechnology firm unveiled findings from its Phase 2a clinical trial evaluating Namodenoson in patients suffering from advanced pancreatic ductal adenocarcinoma (PDAC). Trading activity positioned the stock near $2.97 per share in the wake of the news.

Can-Fite BioPharma Ltd., CANF

The open-label clinical investigation recruited 20 participants — each having experienced disease progression despite undergoing conventional treatment regimens. Among the cohort, fourteen individuals received Namodenoson as third-line treatment, five as second-line intervention, and one as fourth-line therapy.

The clinical trial successfully accomplished its primary safety objective. Namodenoson demonstrated excellent tolerability, exhibiting a safety profile aligned with previous clinical investigations.

An updated survival assessment focusing on eight evaluable third-line patients who maintained survival for a minimum of two months post-treatment initiation revealed median overall survival exceeding five months. This represents a significant benchmark in a disease state characterized by severely limited therapeutic alternatives at advanced stages.

Among this patient subset, 62.5% maintained survival for five months or beyond. Meanwhile, 37.5% achieved survival extending past seven months. Two participants remained alive when data collection concluded.

The second-line treatment cohort yielded a particularly noteworthy finding. A single patient maintained survival beyond 18 months following Namodenoson treatment commencement — establishing the record as the trial’s longest-surviving individual.

Principal Investigator’s Assessment

Prof. Salomon Stemmer, who directs the Phase 2a investigation at the Davidoff Institute of Oncology within Rabin Medical Center in Israel, characterized the Namodenoson monotherapy outcomes as “impressive.”

He highlighted both the advantageous safety characteristics and the extended survival observed among a patient subset as compelling evidence of meaningful biological activity warranting additional exploration. He identified combination therapy with chemotherapy as the rational progression for subsequent research.

Prelaboratory research has demonstrated Namodenoson’s capacity to amplify the anti-tumor effects of chemotherapeutic compounds in pancreatic cancer experimental models, establishing the scientific foundation for this advancement.

Future Development Plans

Can-Fite has outlined plans to advance Namodenoson into a Phase 2b combination trial incorporating chemotherapy, leveraging both the Phase 2a clinical outcomes and supporting prelaboratory evidence.

The biotechnology company maintains a market capitalization of merely $5.87 million alongside a GF Score of 55 out of 100, indicating moderate growth prospects while registering weak scores in profitability (1/10) and financial strength (4/10).

No insider transaction activity—neither purchases nor sales—has been recorded for CANF shares throughout the preceding 12-month period.

The current P/S ratio registers at 5.32. For a clinical-stage biotechnology enterprise of this scale, equity price movements are being propelled by trial outcomes rather than fundamental financial metrics.